Cáncer de pulmón

  1. Resano Barrio, María Pilar
  2. Anta Mejía, Y.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2014

Título del ejemplar: Enfermedades respiratorias (V): Enfermedades neoplásicas y genéticas

Serie: 11

Número: 67

Páginas: 3983-3994

Tipo: Artículo

DOI: 10.1016/S0304-5412(14)70873-X DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El cáncer de pulmón es la primera causa de muerte entre los pacientes diagnosticados de enfermedad tumoral. El principal factor de riesgo para desarrollarlo es el tabaquismo, aunque también pueden influir otros factores como los ambientales, ocupacionales, la dieta y la carga genética. Los pacientes con cáncer de pulmón suelen presentar síntomas cuando la enfermedad está avanzada. Debido a su elevada mortalidad, existe un gran interés en el cribado de esta enfermedad basada en la TC de baja radiación con resultados positivos en pacientes de alto riesgo. En los últimos años, se han producido grandes avances en el tratamiento del cáncer de pulmón, tanto en estadios precoces basados en nuevas técnicas de radioterapia en pacientes inoperables como en el caso de la enfermedad metastásica, gracias al descubrimiento de marcadores moleculares que permiten hacer un tratamiento dirigido e individualizado.

Referencias bibliográficas

  • Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM. Reduced lung cancer mortality with low dose computed tomographic screening. New Eng J Med. 2011;365:395-409.
  • Albain KS, Swann RS, Rusch VW, Turrisi AT, Turrisi AT, Shepherd FA, Smith C. Radiotherapy plus chemotherapy with or without surgical resection for stage III non small cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379- 88.
  • Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non small cell lung cancer. J Clin Oncol. 2010;28:2181-90.
  • Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early stage and oligometastatic non small cell lung cancer: evidence for changing paradigms. Cancer Res Treat. 2011;43:75-82.
  • David E, Midthun MD. Overview of the risk factors, pathology, and clinical manifestations of lung cancer. UptoDate 2014.
  • De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J. 2007;29:995-1002.
  • Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer. ACCP evidence-Based Clinical Practice Guidelines (2nd ed). Chest. 2007;132:202S-20S.
  • Didkowska J, Manczuk M, McNeill A, Powles J, Zatonski W. Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics. BMJ. 2005;331:189.
  • Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA. Stereotactic body radiation therapy for early stage non small cell lung carcinoma: four year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677-82.
  • Goldstraw P. Staging manual in thoracic oncology. 1st ed. Florida: Editorial Rx Press; 2009.
  • Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification for malignant tumours. J Thorac Oncol. 2007;2:706-14.
  • Gómez JJ, de Castro J, Concha A, Felip E, Isla, D, López-Ríos F. Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. Rev Esp Patol. 2012;45(1):14-28.
  • Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer: A systematic review and meta-analysis. Eur J Cancer. 2009;45:1389-96.
  • Heinzerling JH, Kavanagh B, Timmerman RD. Stereotactic ablative radiation therapy for primary lung tumors. Cancer J. 2011;17:28-32.
  • Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS. Early Lung Cancer Action Project: Overall Design and Findings From Baseline Screening. Lancet. 1999;354:99-105.
  • Henschke CI, Yankelevitz DF, McCauley DI, Sone S, Hanaoka T, Markowitz S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763-71.
  • Hughes JM, Weill H. Asbestos and man-made fibers. Epidemiology of lung cancer. New York: Marcel Dekker; 1994. p. 185.
  • Hwangbo B, Kim SK, Lee HS, Lee HS, Kim MS, Lee JM. Application of endobronchial ultrasound guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable non small cell lung cancer. Chest. 2009;135:1280-7.
  • Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G. A randomized study of lung cancer screening with spiral computed tomography: three year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180:445-53.
  • Jonathan M, Samet, MD. Secondhand smoke exposure: effects in adults. Literature review current through. UptoDate 2014.
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG. Anaplastic Lymphoma Kinase inhibitios in non small cell Lung Cancer. N Engl J Med. 2010;363:1693-703.
  • López Encuentra A, Callol Sánchez L, Martín de Nicolás Serrahima JL, Moreno Mata N. Carcinoma broncogénico. Manual de neumología clínica. 2º ed. Madrid: Ergón; 2009. p. 267-87.
  • Mannino DM. Cigarette smoking and other risk factors for lung cancer. UptoDate 2014.
  • Micames CG, McCrory DC, Pavey DA, Jowell PS, Gress FG. Endoscopic ultrasound guided fine needle aspiration for non small cell lung cancer staging. A sistematic review and metaanalysis. Chest. 2007;131:539-48.
  • Midthun DE. Overview of the risk factors, pathology, and clinical manifestations of lung cáncer. Literature review current through. UptoDate 2014.
  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
  • Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306:1865-73.
  • Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-59.
  • Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc. 1985;60:158.
  • Quint LE, Francis IR, Gross BH. Conventional imaging of non small cell lung cancer. Lung cancer. Principles and practice. Philadelphia (USA): Lippincott Williams & Wilkins; 2005. p. 315-44.
  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non small cell lung cancer (EURTAC): a multicentre, open label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46.
  • Rosell R, Gómez Codina J, Camps C, Maestre J, Padille J, Cantó A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non small cell lung cancer. N Engl J Med. 1994;330:153-8.
  • Sánchez de Cos J, Hernández J, Jiménez MF, Padrones S, Rosell A, Rami R. Normativa SEPAR sobre estadificación del cáncer de pulmón. Arch Bronconeumol. 2011;47:454-65.
  • Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non small cell lung cancer. J Thorac Oncol. 2010;5:1416-23.
  • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non small cell lung cancer. J Clin Oncol. 2008;26:3543-51.
  • Serra M, Rami R, Belda J, Call S, González G, Bastús R. Análisis de los falsos negativos de la exploración quirúrgica sistemática del mediastino en pacientes afectos de un carcinoma broncogénico candidatos a tratamiento quirúrgico. Arch Bronconeumol. 2005;41Especial Congreso:90-1.
  • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-94.
  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
  • Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E. Non invasive mediastinal staging of lung cancer. ACCP Evidenced Based Clinical Practice. Guidelines (2nd ed). Chest. 2007;132:178S-201S.
  • Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Stu-dy Groups. J Clin Oncol. 2008;26:5043-51.
  • Travis WD, Brambilla E, Noguchi M, Daniels M, Conron M, Williams RA. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-85.
  • Van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361:2221-9.
  • Van Lersel CA, de Koning HJ, Draisma G, Mali WPTM, Scholten ET, Nackaerts K. Risk based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multislice CT screening trial (NELSON). Inter J Cancer. 2007;120(4):868-74.
Fuente de los datos: Dialnet